ClinicalTrials.gg
CompletedNCT00839306Updated Feb 8, 2016Results posted

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

A Phase 3 interventional study of Rabeprazole ER and Ranitidine in Gastroesophageal Reflux Disease (GERD), sponsored by Eisai Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
11th of 39
240 · median 100
Started
2008
with 7 others
Phase 3
16 of 40
none open now
Registered
27th of 40
by date
Lead sponsor
9 of 40
Eisai Inc.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 11th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2008, is one of 16 in phase 3, and was the 27th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

Read the detailed description

This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups, rabeprazole extended release 50 mg (once daily) or ranitidine 150 mg (twice daily).

Please note that this study is not a duplicate of E3810-G000-305; this is a separate study being conducted along with -305.

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • Gastroesophageal
  • Reflux
  • Disease
  • GERD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY INCLUSION CRITERIA:

1. Prior completion of Study E3810-G000-302 or -303. Subjects will need to have healed erosive esophagitis (absence of esophageal mucosal breaks or erosions) confirmed by EGD and sustained resolution of heartburn at Visit 4 or 5 of Study E3810-G000-302 or -303.

KEY EXCLUSION CRITERIA:

  1. Esophageal motility disorders (achalasia, scleroderma, or esophageal spasm).
  2. Barrett's esophagus or esophageal stricture.
  3. Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine receptor antagonists (H2RA), antacids, sucralfate, misoprostol, prokinetics or drugs with significant anticholinergic effects throughout the study.
  4. Subjects who require chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral (>= 20 mg/day prednisone or equivalent), or aspirin (->; 325 mg/day).
  5. Significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities that would be likely to interfere with the conduct of the study, the interpretation of study results, or the health of the subject during the study.
  6. Any condition that would make the subject, in the opinion of the Investigator or Sponsor, unsuitable for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    1

    Drug: Rabeprazole ER

  • Active comparator
    2

    Drug: Ranitidine

Interventions

  • 50 mg capsule, taken orally, once daily for 26 weeks.

    Also known as: Aciphex

  • 150 mg capsule, taken orally, twice daily for 26 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

    eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the oesophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

    Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities).

    Time frame: Baseline to Week 26

07

Results

Posted Nov 16, 2015

Participant flow

Participants were eligible for this study if they had completed one of the healing studies (E3810-G000-302 or E3810-G000-303), had no evidence of oesophageal erosions, had sustained heartburn resolution, and had no record of any serious adverse event (SAE) related to study medication during the healing study.

Participant flow — Overall Study
MilestoneRAN 150mg BIDRAB ER 50mg QD
Started60177
Completed35134
Not completed2543
Withdrew: Adverse event35
Withdrew: Lost to follow-up69
Withdrew: Withdrawal by subject57
Withdrew: Lack of efficacy54
Withdrew: Other618

Outcome measures

SecondaryPercentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26

Heartburn or other GERD-associated symptoms (regurgitation, epigastric or chest pain, dysphagia, belching, bloating, early satiety, other) was based on a 4-point Likert scale that included the following: None (No symptoms); Mild (Awareness of symptoms but easily tolerated); Moderate (Discomforting symptom sufficient to cause interference with normal activities including sleep); Severe (Incapacitating symptom, inability to perform normal activities).

Time frame:
Baseline to Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants With Investigator-recorded Sustained Resolution of Heartburn at Week 26
Percentage of ParticipantsRAN 150mg BIDRAB ER 50mg QD
Yes8.353.7
No16.717.5
Missing7528.8
PrimaryPercentage of Participants With Maintenance of Complete Healing of eGERD at Week 26

eGERD (erosive gastroesophageal reflux disease) healing measured by the Time-to-Relapse of Oesophageal Erosions using an Esophagogastroduodenoscopy (EGD). Lesions were identified and graded using the following Los Angeles (LA) classification of Oesophagitis: Not Present: No breaks (erosions) in the oesophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

Time frame:
Baseline to Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 26
Percentage of ParticipantsRAN 150mg BIDRAB ER 50mg QD
Percentage of Participants With Maintenance of Complete Healing of eGERD at Week 2631.788.4

Adverse events

Collected over For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to approximately 30 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RAN 150mg BID—1/56 (1.8%)22/56 (39.3%)
RAB ER 50mg QD—3/170 (1.8%)42/170 (24.7%)
Most frequent serious events
Most frequent serious events
EventRAN 150mg BIDRAB ER 50mg QD
PancreatitisGastrointestinal disorders1/560/170
Chest painGeneral disorders0/561/170
GastroenteritisInfections and infestations0/561/170
PneumoniaInfections and infestations0/561/170
DehydrationMetabolism and nutrition disorders0/561/170
Most frequent other events
Most frequent other events
EventRAN 150mg BIDRAB ER 50mg QD
Hiatus herniaGastrointestinal disorders6/567/170
GastritisGastrointestinal disorders4/5617/170
Erosive oesophagitisGastrointestinal disorders5/562/170
SinusitisInfections and infestations1/5610/170
DyspepsiaGastrointestinal disorders3/564/170
Acquired oesophageal webGastrointestinal disorders3/562/170

Baseline characteristics

Age, Customized
Age, Customized(Years)RAN 150mg BIDRAB ER 50mg QDTotal
Mean47.5 ± 13.5547.5 ± 12.0647.5 ± 12.43
Sex: Female, Male
Sex: Female, Male(Participants)RAN 150mg BIDRAB ER 50mg QDTotal
Female2888116
Male3289121
08

Study locations

4 sites
  • Associates, Ltd.
    Moline, Illinois 61265, United States
  • Midwest Clinical
    Moline, Illinois 61265, United States
  • Research
    Moline, Illinois 61265, United States
  • Moline, Illinois 61265, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Aug 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2009
First posted
Feb 9, 2009
Start
Aug 2008
Primary completionActual
Aug 2009
CompletionActual
Jan 2010
Results first posted
Nov 16, 2015
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00839306
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 9, 2009
Start date
Aug 2008
Primary completion
Aug 2009
Completion
Jan 2010
Results posted
Nov 16, 2015
Last update
Feb 8, 2016

Study contacts

Guillermo Rossiter, M.D.
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion